These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 32130098

  • 1. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R, Vaz S, Rebelo T, Figueiredo-Dias M.
    Acta Med Port; 2020 Mar 02; 33(3):198-201. PubMed ID: 32130098
    [Abstract] [Full Text] [Related]

  • 2. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, Dahlab A, Prétet JL.
    BMC Public Health; 2015 May 02; 15():453. PubMed ID: 25934423
    [Abstract] [Full Text] [Related]

  • 3. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA, Segal SV, Méndez JH.
    Medicina (B Aires); 2018 May 02; 78(5):315-328. PubMed ID: 30285924
    [Abstract] [Full Text] [Related]

  • 4. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
    Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, Copeland G, Cozen W, Peters ES, Huang Y, Saber MS, Altekruse S, Goodman MT, HPV Typing of Cancers Workgroup.
    J Natl Cancer Inst; 2015 Jun 02; 107(6):djv086. PubMed ID: 25925419
    [Abstract] [Full Text] [Related]

  • 5. Cancers attributable to human papillomavirus infection.
    Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.
    Sex Health; 2010 Sep 02; 7(3):244-52. PubMed ID: 20719211
    [Abstract] [Full Text] [Related]

  • 6. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L.
    Eur J Cancer; 2015 Sep 02; 51(13):1732-41. PubMed ID: 26121913
    [Abstract] [Full Text] [Related]

  • 7. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
    Ong KJ, Checchi M, Burns L, Pavitt C, Postma MJ, Jit M.
    Sex Transm Infect; 2019 Feb 02; 95(1):28-35. PubMed ID: 30674687
    [Abstract] [Full Text] [Related]

  • 8. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [Abstract] [Full Text] [Related]

  • 9. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
    Sehnal B, Vojáčková N, Driák D, Kmoníčková E, Vaňousová D, Maxová K, Neumannová H, Sláma J.
    Klin Onkol; 2014 Dec 29; 27(4):239-46. PubMed ID: 25115712
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.
    Vaccine; 2013 Nov 22; 31 Suppl 8(0 8):I1-31. PubMed ID: 24229716
    [Abstract] [Full Text] [Related]

  • 11. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT, Castellsagué X, Garland SM.
    Vaccine; 2012 Nov 20; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [Abstract] [Full Text] [Related]

  • 12. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
    Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK.
    J Natl Cancer Inst; 2013 Feb 06; 105(3):175-201. PubMed ID: 23297039
    [Abstract] [Full Text] [Related]

  • 13. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.
    PLoS One; 2014 Feb 06; 9(2):e88323. PubMed ID: 24505474
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 15. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
    Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK.
    Vaccine; 2015 Sep 22; 33(39):5042-50. PubMed ID: 26271829
    [Abstract] [Full Text] [Related]

  • 16. Five-year relative survival for human papillomavirus-associated cancer sites.
    Razzaghi H, Saraiya M, Thompson TD, Henley SJ, Viens L, Wilson R.
    Cancer; 2018 Jan 01; 124(1):203-211. PubMed ID: 29105738
    [Abstract] [Full Text] [Related]

  • 17. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
    Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J.
    Int J Cancer; 2012 Nov 01; 131(9):1969-82. PubMed ID: 22623137
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 19. The HPV infection in males: an update.
    Giraldi G, De Luca d'Alessandro E.
    Ann Ig; 2012 Aug 20; 24(6):497-506. PubMed ID: 23234187
    [Abstract] [Full Text] [Related]

  • 20. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
    Malinova M.
    Akush Ginekol (Sofiia); 2015 Aug 20; 54 Suppl 1():25-31. PubMed ID: 26137767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.